JP2023533203A5 - - Google Patents

Info

Publication number
JP2023533203A5
JP2023533203A5 JP2022580090A JP2022580090A JP2023533203A5 JP 2023533203 A5 JP2023533203 A5 JP 2023533203A5 JP 2022580090 A JP2022580090 A JP 2022580090A JP 2022580090 A JP2022580090 A JP 2022580090A JP 2023533203 A5 JP2023533203 A5 JP 2023533203A5
Authority
JP
Japan
Prior art keywords
alkyl
unsubstituted
compound according
substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022580090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533203A (ja
JP7781792B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038618 external-priority patent/WO2021262810A1/en
Publication of JP2023533203A publication Critical patent/JP2023533203A/ja
Publication of JP2023533203A5 publication Critical patent/JP2023533203A5/ja
Priority to JP2025203650A priority Critical patent/JP2026035702A/ja
Application granted granted Critical
Publication of JP7781792B2 publication Critical patent/JP7781792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022580090A 2020-06-24 2021-06-23 セレブロン結合化合物、その組成物及びそれによる治療方法 Active JP7781792B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025203650A JP2026035702A (ja) 2020-06-24 2025-11-26 セレブロン結合化合物、その組成物及びそれによる治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043555P 2020-06-24 2020-06-24
US63/043,555 2020-06-24
PCT/US2021/038618 WO2021262810A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025203650A Division JP2026035702A (ja) 2020-06-24 2025-11-26 セレブロン結合化合物、その組成物及びそれによる治療方法

Publications (3)

Publication Number Publication Date
JP2023533203A JP2023533203A (ja) 2023-08-02
JP2023533203A5 true JP2023533203A5 (enExample) 2024-06-07
JP7781792B2 JP7781792B2 (ja) 2025-12-08

Family

ID=79032408

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580090A Active JP7781792B2 (ja) 2020-06-24 2021-06-23 セレブロン結合化合物、その組成物及びそれによる治療方法
JP2025203650A Pending JP2026035702A (ja) 2020-06-24 2025-11-26 セレブロン結合化合物、その組成物及びそれによる治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025203650A Pending JP2026035702A (ja) 2020-06-24 2025-11-26 セレブロン結合化合物、その組成物及びそれによる治療方法

Country Status (16)

Country Link
US (3) US11634407B2 (enExample)
EP (1) EP4171566A4 (enExample)
JP (2) JP7781792B2 (enExample)
CN (2) CN120441548A (enExample)
AR (1) AR122723A1 (enExample)
AU (1) AU2021296833A1 (enExample)
BR (1) BR112022025933A2 (enExample)
CA (1) CA3182325A1 (enExample)
CL (1) CL2022003719A1 (enExample)
CO (1) CO2022018653A2 (enExample)
IL (1) IL299256A (enExample)
MX (1) MX2022015757A (enExample)
PE (1) PE20231746A1 (enExample)
SA (1) SA522441857B1 (enExample)
TW (1) TWI924678B (enExample)
WO (1) WO2021262810A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN115996918A (zh) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
IL299256A (en) 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith
KR20240026939A (ko) * 2021-06-25 2024-02-29 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
JP2025531869A (ja) 2022-09-09 2025-09-25 イノヴォ セラピューティクス、インコーポレイテッド CK1αおよびDUAL CK1α/GSPT1分解化合物
AU2024344247A1 (en) 2023-09-19 2026-05-07 Kancure Pte. Ltd. Survivin-targeted compounds
AU2024392985A1 (en) 2023-12-08 2026-06-04 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN110023297A (zh) * 2016-07-08 2019-07-16 詹森药业有限公司 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2020051260A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
BR112021011968A2 (pt) 2018-12-19 2021-09-08 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
AU2019404022A1 (en) 2018-12-19 2021-07-08 Celgene Corporation Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
IL299256A (en) * 2020-06-24 2023-02-01 Celgene Corp Cerebellum binding compounds, their compounds and methods of treatment with them
ES3047718T3 (en) 2020-06-24 2025-12-04 Celgene Corp Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Similar Documents

Publication Publication Date Title
JP2023531709A5 (enExample)
JP2023531495A5 (enExample)
JP2024526191A5 (enExample)
JP2024520481A5 (enExample)
JP2022512482A5 (enExample)
JP7759877B2 (ja) 治療用化合物
JP2022520448A5 (enExample)
JP2019094345A5 (enExample)
JP2020506951A5 (enExample)
JP2022510925A5 (enExample)
JP2021514001A5 (enExample)
JP2019537559A5 (enExample)
JP2025024130A5 (enExample)
JP2011509309A5 (enExample)
JP2015533782A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2015516420A5 (enExample)
JP2024516033A5 (enExample)
JP2022511477A5 (enExample)
JP2022514347A5 (enExample)
JP2021523168A5 (enExample)
JP2014514290A5 (enExample)
JP2022534704A5 (enExample)
JP2008513485A5 (enExample)
CA2617991A1 (en) N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JP2014520108A5 (enExample)